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OBJECTIVES The study examined the electrocardiographic and electrophysiologic characteristics in relation
to programmed ventricular stimulation (PVS)-induced ventricular fibrillation (VF), as well as
the implications of PVS-induced VF on the recurrence of cardiac events in symptomatic
Brugada syndrome.
BACKGROUND Brugada syndrome is characterized by ST-segment elevation in the right precordial leads
(V1–V3) and an episode of VF.
METHODS Thirty-four symptomatic patients with Brugada syndrome (33 men and 1 woman; 44  12
years old) were classified into two groups according to the inducibility of VF with PVS: 22
patients with induced VF requiring direct cardioversion for termination (Induced VF group)
and 12 patients without induced VF (Noninduced VF group).
RESULTS The induced VF group showed a longer QRS duration, a higher incidence of right bundle
branch block and late potentials detected on the signal-averaged electrocardiogram, longer
His-ventricular intervals and a longer conduction time from the RVOT to the left ventricle
at extrastimulation than those in the non-induced VF group. However, there was no significant
difference in the recurrence of cardiac events (VF documented by an implantable cardioverter-
defibrillator and sudden cardiac death) between the two groups (8 [36%] of 22 patients vs. 7
[58%] of 12 patients) during long-term follow-up (range 1 to 149 months; mean 38).
CONCLUSIONS Our data suggest that induction of VF by PVS depends on the severity of depolarization
abnormalities but does not predict the recurrence of cardiac events in symptomatic Brugada
syndrome, indicating that both depolarization and repolarization abnormalities are important
in the development of VF. (J Am Coll Cardiol 2002;39:1799–805) © 2002 by the
American College of Cardiology Foundation
In 1992, Brugada and Brugada described eight patients with
a history of aborted sudden death due to ventricular fibril-
lation (VF) with a distinct electrocardiographic (ECG)
pattern, consisting of right bundle branch block (RBBB)
with ST-segment elevation in the right precordial leads
(V1–V3) and a normal QT interval in the absence of any
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structural heart disease (1). Thereafter, patients with these
unique ECG abnormalities have been recognized as a
distinct subgroup with a high risk of sudden cardiac death
(SCD) (2–6). The only gene to be linked to the Brugada
syndrome was first reported by Chen et al. (7), who found
mutations in the cardiac sodium channel gene, SCN5A.
Some clinical studies have reported the presence of depo-
larization abnormalities and the possibility of a subclinical
form of right ventricular cardiomyopathy in this syndrome
(8–10). Other experimental and clinical studies have sug-
gested, however, that heterogeneous repolarization across
the ventricular wall of the right ventricular outflow tract
(RVOT) was responsible for the ST-segment elevation and
genesis of VF (11–15). Although both depolarization and
repolarization abnormalities seem to be present in this
syndrome, it is still unclear how these abnormalities interact
and contribute to its pathogenesis. Moreover, the electro-
physiologic characteristics and implications of programmed
ventricular stimulation (PVS)-induced VF remain unclear
in patients with Brugada syndrome. Therefore, we system-
atically carried out this study to examine: 1) the ECG and
electrophysiologic characteristics in relation to PVS-
induced VF; and 2) the implications of PVS-induced VF on
the recurrence of cardiac events during long-term follow-up
in symptomatic patients with Brugada syndrome.
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METHODS
Study group. From September 1989 through February
2000, we systematically studied 34 consecutive patients with
symptomatic Brugada syndrome who were admitted to the
National Cardiovascular Center, Osaka, Japan. Symptom-
atic Brugada syndrome was diagnosed if the following
criteria were fulfilled (16): 1) a history of apparent syncope,
or aborted cardiac arrest with or without documented VF; 2)
spontaneously documented persistent or transient ST-
segment elevation (coved and/or saddle-back type) in the
right precordial leads (V1–V3), with or without some degree
of RBBB; 3) a normal corrected QT interval 0.44 s; 4)
normal findings on physical examination and normal labo-
ratory values; and 5) no evidence of structural heart disease
demonstrated on the cardiac echocardiogram, coronary
angiogram, right and left ventriculograms, radionucleogram
and magnetic resonance image. All but one of the patients
were male (age range 19 to 68 years; mean 44  12). All 34
patients had episodes of syncope, and 23 patients had a
history of aborted cardiac arrest before diagnosis. Ventric-
ular fibrillation was documented in 22 patients, and four
patients had family members who died suddenly (Table 1).
Twelve-lead ECG. A 12-lead ECG was recorded during
sinus rhythm in the absence of any anti-arrhythmic drugs.
The RR interval, PR interval and QRS duration were
measured in lead V5 or V6. We defined RBBB by the
presence of a widened S wave in the left precordial lead (V6)
and a QRS duration 0.10 s; incomplete RBBB was
defined by a QRS duration0.12 s; and complete RBBB by
a QRS duration 0.12 s.
Signal-averaged ECG. The late potential (LP) was ana-
lyzed using a signal-averaged ECG system (Arrhythmia
Research Technology 1200EPX, Milwaukee, Wisconsin).
Analysis of the signal-averaged ECG was based on the
quantitative time-domain measurements of the filtered vec-
tor magnitude of the orthogonal Frank X, Y and Z leads.
The QRS complexes were amplified, digitized, averaged
(350 to 400 beats) and filtered with a high-pass filter (40
Hz). Three parameters were assessed using a computer
algorithm: 1) the total filtered QRS duration; 2) the root
mean square voltage of the terminal 40 ms of the filtered
QRS complexes (V40); and the duration of low-amplitude
signals40 V of the filtered QRS complex (T40). The LP
was considered present when two criteria (V40 18 V and
T40  38 ms) were fulfilled.
Electrophysiologic study. An electrophysiologic study was
performed in all patients without any anti-arrhythmic drugs
after informed consent was obtained. The atrio-His interval
and the His-ventricular interval were measured during
constant right atrial pacing at a cycle length of 600 ms.
Programmed ventricular stimulation was performed at 2-ms
and twice the diastolic threshold current from the right
ventricular apex (RVA) and the RVOT, using two basic
cycle lengths (500 and 600 ms) and a maximum of triple
extrastimuli. Inducibility of ventricular arrhythmias was
tested first at the RVA using single and double extrastimuli,
and in case of noninducibility, it was tested at the RVOT
using single and double extrastimuli. If ventricular arrhyth-
mias were not induced using up to double extrastimuli,
triple extrastimuli were introduced from the RVA first, and
then from the RVOT. The end points of PVS were either
induction of VF associated with hemodynamic collapse or
completion of the PVS protocol. Ventricular fibrillation was
defined as a polymorphic ventricular arrhythmia with an
R-R interval200 ms (300 beats/min) and hemodynamic
decompensation requiring direct cardioversion for termina-
tion. Nonsustained polymorphic ventricular tachycardia
(VT) was defined as polymorphic ventricular arrhythmia of
5 beats and terminating spontaneously. If VF was not
induced during PVS using up to double extrastimuli at the
RVOT, we measured the conduction time from the RVOT
to the lateral wall of the left ventricle during double
extrastimuli from the RVOT. The longest conduction time
between the stimulus artifact at the RVOT and the ventric-
ular electrogram at the distal coronary sinus was used as a
parameter of conduction delay via the ventricular septum at
a basic cycle length of 500 ms (S1V1), at a first extrastimulus
(S2V2) and at a second extrastimulus (S3V3), respectively.
Thirty-four patients were classified into two groups
according to the inducibility of VF: 22 patients with
induced VF requiring direct cardioversion for termination
(induced VF group) and 12 patients without induced VF
(noninduced VF group). We compared the electrocardio-
graphic and electrophysiologic parameters and the recur-
rence of cardiac events between the two groups. In the
noninduced VF group, nonsustained polymorphic VT was
induced in eight patients, but no ventricular arrhythmias
were induced in the other four patients.
Therapy and follow-up. All patients were followed up at
the outpatient clinics of the National Cardiovascular Cen-
ter. Because all patients were symptomatic (apparent syn-
cope or aborted cardiac arrest) in the present study, implan-
tation of an implantable cardioverter-defibrillation (ICD)
was recommended in all patients. Some earlier patients, who
were admitted when an ICD was not available in Japan and
continued to refuse implantation later, were treated with
Abbreviations and Acronyms
ECG  electrocardiogram
ICD  implantable cardioverter-defibrillator
LPs  late potentials
PVS  programmed ventricular stimulation
RBBB  right bundle branch block
RVA  right ventricular apex
RVOT right ventricular outflow tract
SCD  sudden cardiac death
T40  duration of low-amplitude signals 40 V of
the filtered QRS complex
V40  root mean square voltage of the terminal 40 ms
of the filtered QRS complex
VF  ventricular fibrillation
VT  ventricular tachycardia
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Table 1. Clinical and Electrocardiographic Data
Patient No.
Age
(yrs) Gender
Family
History
Clinical Events 12-Lead ECG SAECG
Syncope
Documented
VF
Aborted
Cardiac Arrest
PQ
(ms)
QRS
(ms) QTc (s)
ST-Segment
Elevation RBBB
TFQRS
(ms)
V40
(V)
T40
(ms) LPs
Induced VF group
1 21 M     168 83 0.33 V1–V3 — 117 18.7 30 
2 51 M     162 96 0.42 V1–V3 — 89 25.5 31 
3 38 M     188 94 0.41 V1,V2 IRBBB 126 7.6 51 
4 38 M     186 106 0.41 V1,V2 IRBBB 123 9.9 63 
5 51 M     186 101 0.33 V1–V3 IRBBB 118 3.5 49 
6 37 M     166 104 0.40 V1–V3 IRBBB 132 15.5 47 
7 63 M     189 106 0.44 V1–V3 IRBBB 116 4.7 50 
8 50 M     168 106 0.40 V1–V3 IRBBB 126 8.0 66 
9 48 M     165 112 0.42 V1–V3 IRBBB 127 5.8 69 
10 27 M     166 104 0.39 V1–V3 IRBBB 113 14.0 45 
11 63 M     194 122 0.40 V1–V4 CRBBB 153 10.6 85 
12 47 M     191 128 0.41 V1–V3 CRBBB 144 6.2 60 
13 57 M     190 138 0.42 V1,V2 CRBBB 165 4.0 70 
14 42 M     149 114 0.42 V1–V3 IRBBB 131 5.3 53 
15 52 M     183 128 0.43 V1–V3 CRBBB 139 11.3 62 
16 57 M     149 114 0.38 V1–V3 CRBBB 134 11.0 84 
17 68 M     160 102 0.39 V1–V3 IRBBB 115 9.2 50 
18 50 M     148 116 0.43 V1,V2 IRBBB 136 7.8 64 
19 48 M     236 108 0.43 V1–V3 IRBBB 139 6.1 62 
20 33 M     175 136 0.39 V1,V2 CRBBB 113 14.0 45 
21 27 M     154 104 0.42 V1–V3 IRBBB 110 18.0 36 
22 42 M     192 106 0.40 V1 IRBBB 102 15.5 41 
Mean  SD 46  12 176  20 110  13* 0.40  0.03 126  17* 10.6  5.6* 55  15*
Noninduced VF group
1 41 M     182 94 0.40 V1–V3 — 107 29.7 25 
2 46 M     164 91 0.43 V1–V3 — 103 11.2 42 
3 29 M     194 84 0.41 V1,V2 — 123 9.2 62 
4 19 M     176 80 0.39 V1,V2 — 103 20.9 26 
5 32 M     190 85 0.36 V1,V2 — 93 26.5 24 
6 61 M     176 106 0.43 V1–V3 — 107 10.6 42 
7 35 M     196 102 0.41 V1,V2 IRBBB 102 NA NA 
8 47 M     133 103 0.37 V1–V3 IRBBB 117 33.1 23 
9 44 M     165 111 0.39 V1,V2 IRBBB 119 9.0 54 
10 43 M     168 94 0.38 V1–V3 — 120 10.2 50 
11 23 F     162 96 0.43 V1,V2 — 97 33.5 28 
12 49 M     160 108 0.41 V1,V2 IRBBB 115 11.6 46 
Mean  SD 39  12 172  18 96  10 0.40  0.02 109  10 18.7  10.2 38  14
*p  0.01 vs. Noninduced VF group.
CRBBB  complete right bundle branch block; ECG  electrocardiogram; IRBBB  incomplete right bundle branch block; LPs  late potentials; NA  not available; PQ  PQ interval; QRS  QRS duration; QTc  corrected
QT interval; SAECG  signal-averaged electrocardiogram; TFQRS  total filtered QRS duration; T40  duration of low-amplitude signals 40 V in the terminal position of the SAECG-QRS complexes; V40  root mean square
voltage in the terminal 40 ms of the SAECG-QRS complexes; VF  ventricular fibrillation;   present;   absent.
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anti-arrhythmic drugs (disopyramide or amiodarone). Pro-
pranolol, a beta-blocker, was added in patients in whom an
ICD was implanted, and any inappropriate cardioversion
was documented as being due to sinus tachycardia or atrial
fibrillation. Special attention was paid to recurrences of
symptomatic arrhythmias. The end points were either ap-
parent syncope, SCD or VF documented in the storage
memory of the ICD. Patients who could not be followed up
for more than one year were excluded from the present
study.
Statistical analysis. Quantitative data are presented as the
mean value SD and were analyzed by using the two-tailed
Student t test. Categorical data are presented as absolute
and were analyzed by the chi-square test. Kaplan-Meier
life-table analysis was used to determine the differences in
event-free survival rates between the two groups. A p value
0.05 was regarded as significant.
RESULTS
Electrocardiographic characteristics. Table 1 shows the
ECG data, including 12-lead and signal-averaged ECGs, of
the two patient groups. The induced VF group had a longer
QRS duration than the noninduced VF group (110 13 vs.
96  10 ms; p  0.01), whereas the RR interval, the PQ
interval and the corrected QT interval were not different
between the two groups. The induced VF group also
showed higher incidences of complete or incomplete RBBB
than the noninduced VF group (20 [91%] of 22 patients vs.
4 [33%] of 12 patients; relative risk 2.72, p  0.01).
Moreover, the induced VF group had longer total filtered
QRS duration, lower V40, and longer T40 on the signal-
averaged ECG than the non-induced VF group (total
filtered QRS duration: 126 17 vs. 109 10 ms, p 0.01;
V40: 10.6  5.6 vs. 18.7  10.2 V, p  0.01; T40: 55 
15 vs. 38  14 ms, p  0.01). The induced VF group also
had a higher incidence of LPs than the noninduced VF
group (19 [86%] of 22 patients vs. 6 [50%] of 12 patients;
relative risk 1.73, p  0.05).
Electrophysiologic characteristics. The electrophysiologic
data of the two patient groups are shown in Table 2. The
induced VF group had a longer His-ventricular interval than
the noninduced VF group (49 9 vs. 41 7 ms; p 0.05),
whereas the atrio-His interval was not different between the
two groups. There were no significant differences in the
effective refractory period at a basic cycle length of 500 ms
at either the RVOT or RVA between the two groups. On
the other hand, the longest conduction times via the
ventricular septum at the first extrastimulus (S2V2) and
second extrastimulus (S3V3) were longer in the induced VF
group than in the noninduced VF group (S2V2: 176  39
vs. 142  26 ms, p  0.05; S3V3: 208  35 vs. 176 
27 ms, p  0.05). Ventricular fibrillation was induced with
a single extrastimulus (in 1 patient from the RVOT), double
extrastimuli (n  12; in 8 from the RVOT and in 4 from
the RVA) and triple extrastimuli (n  9; in 6 from the
RVOT and in 3 from the RVA) in the induced VF group.
Nonsustained polymorphic VT was induced with double
extrastimuli (in 1 patient from the RVOT) and triple
extrastimuli (in 7 patients from the RVOT) in the non-
induced VF group.
Therapy and follow-up. An ICD was implanted in 19 of
22 patients in the induced VF group and in 9 of 12 patients
in the noninduced VF group (Table 3). Propranolol was
added in one patient in the induced VF group and in three
patients in the noninduced VF group. One patient in the
noninduced VF group refused to stop disopyramide after
ICD implantation. Three patients in the induced VF group
and three patients in the noninduced VF group were treated
with anti-arrhythmic drugs only (i.e., disopyramide, amio-
darone or pindolol). The average follow-up periods were 36
 32 months in the induced VF group and 46 45 months
in the noninduced VF group. There was no significant
difference in the recurrence of cardiac events (VF docu-
mented by ICD and SCD) between the two groups (8
[36%] of 22 patients vs. 7 [58%] of 12 patients) during
long-term follow-up. Two patients (1 in the induced VF
group and 1 in the noninduced VF group) who were treated
with disopyramide died suddenly. The ICD effectively
terminated all episodes of VF and prevented SCD. All
episodes occurred during sleep (between 10:00 PM and
9:00 AM), except for three patients: one had VF in the early
morning (8:30 AM), one developed VF at 5:30 PM, and the
other suffered VF at 7:15 PM while awake. A life-table
analysis showing a comparison of the cumulative proportion
of either VF or SCD between the two groups is shown in
Figure 1. There were no significant differences in the
frequency of the recurrence of VF or SCD between the two
groups. It is noteworthy that the first recurrence of cardiac
events was observed within two years in all but three
patients.
DISCUSSION
The major finding of our study was that the induction of VF
by PVS depended on the severity of depolarization abnor-
malities in symptomatic patients with Brugada syndrome.
However, the PVS-induced VF did not predict the recur-
rence of cardiac events during long-term follow-up.
Electrophysiologic and ECG characteristics in Brugada
syndrome. A recently highlighted form of Brugada syn-
drome is characterized by ST-segment elevation in the right
precordial ECG leads (V1–V3), often but not always accom-
panied by apparent RBBB (1–6). Prolongation of the
His-ventricular interval has been demonstrated during elec-
trophysiologic testing in several reports (1–3). Moreover,
several clinical studies have suggested a high incidence of
LPs detected on the signal-averaged ECG in patients with
Brugada syndrome (2,9,10). These are all well-established
hallmarks of depolarization abnormalities. In our 34 symp-
tomatic patients with Brugada syndrome, both the QRS
duration and His-ventricular interval were moderately pro-
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longed (QRS duration: 105  14 ms; His-ventricular
interval: 45  9 ms). Moreover, 24 patients (71%) showed
incomplete (n  18) or complete (n  6) RBBB patterns,
and 25 patients (74%) had LPs on the signal-averaged
ECG. These findings are consistent with previous studies
and suggest the presence of subtle depolarization abnormal-
ities that cannot be reflected as structural abnormalities in
symptomatic Brugada syndrome. Moreover, the longest
conduction time from the RVOT through the ventricular
septum to the lateral left ventricle at the first (S2V2) and
second (S3V3) extrastimulus were 161  38 and 194 
35 ms, respectively, which were both longer than those in
control subjects (unpublished data). Corrado et al. (8)
demonstrated that the latest endocardial ventricular electro-
gram was recorded at the RVOT, suggesting the presence of
a conduction delay at the RVOT. These findings indicate
that depolarization abnormalities may exist mainly at the
RVOT and ventricular septum in patients with Brugada
syndrome.
Implications of PVS-induced VF. In the present study,
VF requiring direct cardioversion for termination was in-
duced in 22 (65%) of the 34 patients. Of note, the VF was
induced by a single extrastimulus or double extrastimuli in
13 of 22 patients. The high inducibility of VF by less
extrastimuli in our symptomatic Brugada patients was con-
cordant with the degree of inducibility reported in several
previous studies (17–19). More importantly, 22 patients
with PVS-induced VF showed longer QRS durations, a
higher incidence of RBBB and LPs, longer His-ventricular
intervals and longer conduction times via the ventricular
Table 2. Electrophysiologic Data
Patient No. AH (ms)
HV
(ms)
ERP (ms) Longest CT (ms) Induced Arrhythmias
RVOT RVA S1V1 S2V2 S3V3 Event Location No. of Extrastimuli
Induced VF group
1 90 53 210 240 160 185 220 VF RVOT T
2 95 32 240 200 NA NA NA VF RVA D
3 100 45 220 250 NA NA NA VF RVOT T
4 98 50 220 230 NA NA NA VF RVOT T
5 100 52 200 210 145 170 200 VF RVOT D
6 NA NA NA NA NA NA NA VF RVA T
7 100 53 NA 220 NA NA NA VF RVA D
8 90 46 200 210 150 180 190 VF RVOT D
9 96 43 220 240 148 165 210 VF RVOT D
10 NA 60 NA NA NA NA NA VF RVA T
11 110 60 240 250 NA NA NA VF RVA T
12 100 70 220 220 230 240 255 VF RVOT D
13 NA NA NA NA NA NA NA VF RVA D
14 135 50 220 220 120 167 185 VF RVOT T
15 120 60 230 230 220 240 260 VF RVOT D
16 100 46 240 230 NA NA NA VF RVOT D
17 80 40 210 220 127 176 241 VF RVOT D
18 100 38 230 190 102 120 150 VF RVOT T
19 158 48 220 230 NA NA NA VF RVOT S
20 120 52 220 210 172 174 210 VF RVOT T
21 90 40 200 200 108 116 168 VF RVOT D
22 114 42 NA 210 NA NA NA VF RVA D
Mean  SD 105  18 49  9* 220  13 222  17 153  42 176  39* 208  35*
Noninduced VF group
1 90 30 210 220 NA NA NA   T
2 85 44 210 210 160 165 180 NSPVT RVOT T
3 90 55 250 240 NA NA NA   T
4 110 40 200 210 120 150 200 NSPVT RVOT T
5 107 40 250 220 145 156 200   T
6 NA 50 NA NA NA NA NA NSPVT RVOT T
7 90 45 240 210 170 170 180 NSPVT RVOT T
8 60 42 210 230 120 130 195 NSPVT RVOT T
9 82 38 210 210 134 152 180 NSPVT RVOT T
10 125 42 220 230 NA NA NA   T
11 95 35 230 240 88 96 132 NSPVT RVOT T
12 105 35 200 200 108 114 138 NSPVT RVOT T
Mean  SD 94  17 41  7 221  19 220  13 131  27 142  26 176  27
*p  0.05 vs. Noninduced VF group.
AH atrio-His interval; CT conduction time; D double extrastimuli; ERP effective refractory period; HVHis-ventricular interval; NA not available, NSPVT
nonsustained polymorphic ventricular tachycardia; RVA  right ventricle apex; RVOT  right ventricle outflow tract; S1V1  longest CT at a basic cycle length of 500 ms;
S2V2  longest CT at the first extrastimulus; S3V3  longest CT at the second extrastimulus; T  triple extrastimuli; VF  ventricular fibrillation;   absent.
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septum at extrastimulation than patients without PVS-
induced VF. These findings suggest that the inducibility of
VF by PVS is related to the severity of depolarization
abnormalities in patients with Brugada syndrome. By con-
trast, no difference was observed in the recurrence of cardiac
events between patients with and those without PVS-
induced VF, suggesting that the induction of VF with PVS
is not able to predict the recurrence of cardiac events in
symptomatic patients with Brugada syndrome. Taken to-
gether with the high recurrence rate of cardiac events (15
[44%] of 34 patients), mostly within two years of long-term
follow-up, an ICD should be implanted regardless of the
induction of VF in symptomatic patients with Brugada
syndrome.
Possible mechanism of VF in Brugada syndrome. Recent
experimental studies have suggested that a prominent tran-
sient outward current (Ito)-mediated phase 1 notch and a
subsequent loss of action potential dome in the epicardial
cells, but not in the endocardial cells in the RVOT, give rise
to voltage gradients across the ventricular wall, resulting in
ST-segment elevation in the right precordial leads and
subsequent VF, due to the mechanism of phase 2 re-entry
(11,12). Although this hypothesis most likely explains the
phenotypic appearance of Brugada syndrome, especially the
ST-segment elevation in leads V1–V3 and the initiating beat
of VF, it remains unclear what can serve as the substrate for
the development of functional reentry to maintain VF. Our
data suggest that depolarization abnormalities mainly lo-
cated at the RVOT and ventricular septum play a significant
role in the maintenance of VF in symptomatic patients with
Brugada syndrome. However, PVS-induced VF did not
predict the recurrence of VF and SCD during long-term
follow-up periods. Therefore, repolarization abnormalities
are necessary in the generation of VF by modulating
ST-segment elevation and providing the initiating beat to
induce VF as a result of phase 2 re-entry.
Study limitations. First, the number of the patients with
Brugada syndrome was small, and only symptomatic pa-
tients were included in the present study. Two recent
multicenter studies have reported the clinical course of both
symptomatic and asymptomatic patients with Brugada syn-
drome during moderate- to long-term follow-up (18,19),
but the prognosis of asymptomatic patients and the value of
PVS in identifying patients at risk are still controversial.
Although the inducibility of VF by PVS and the recurrence
of VF in symptomatic patients in the present study were
quite similar to those reported in the two previous studies,
our data showing the limited value of PVS support the data
of Priori et al. (18) rather than the data of Brugada et al.
Table 3. Therapy and Follow-Up
Patient No.
Follow-Up
(month) Therapy
Recurrent
Event
Induced VF group
1 76 Amiodarone, 200 mg —
2 29 ICD —
3 5 Disopyramide, 600 mg SD
4 93 Amiodarone, 200 mg —
5 63 ICD —
6 19 ICD VF
7 8 ICD VF
8 48 ICD —
9 46 ICD —
10 3 ICD VF
11 115 ICD  propranolol, 30 mg —
12 76 ICD —
13 10 ICD VF
14 40 ICD —
15 47 ICD —
16 38 ICD —
17 9 ICD VF
18 22 ICD —
19 1 ICD VF
20 27 ICD —
21 10 ICD VF
22 18 ICD —
Mean  SD 36  32
Median 28
Noninduced VF group
1 113 Disopyramide, 600 mg SD
2 24 ICD VF
3 29 ICD  propranolol, 60 mg VF
4 65 ICD  propranolol, 60 mg —
5 11 ICD  propranolol, 60 mg VF
6 21 ICD VF
7 149 ICD  Disopyramide, 600 mg —
8 17 ICD VF
9 75 Amiodarone, 200 mg —
10 26 ICD —
11 20 Pindolol, 30 mg —
12 6 ICD VF
Mean  SD 46  45
Median 25
ICD  implantable cardioverter-defibrillator; SCD  sudden cardiac death; VF 
ventricular fibrillation;   none.
Figure 1. Kaplan-Meier curves of recurrent cardiac events (sudden cardiac
death and ventricular fibrillation [VF] documented by an implantable
cardioverter-defibrillator) in 22 patients with programmed ventricular
stimulation (PVS)-induced VF (solid line) and in 12 patients without
PVS-induced VF (dotted line).
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(19). Although the small number of subjects, and the
presence of only patients who were symptomatic, are major
weaknesses of the present study, all 34 patients are probands
from different families and underwent the electrophysi-
ologic study using a uniform protocol in a single center.
Therefore, further prospective study using a uniform pro-
tocol in a large population will be needed to draw conclu-
sions about the prognostic value of PVS in both symptom-
atic and asymptomatic patients with Brugada syndrome.
Second, one-third of the patients were treated with
anti-arrhythmic agents alone or in addition to ICD implan-
tation, which may add a confounding variable in interpret-
ing the data on arrhythmia recurrence. However, no signif-
icant differences were observed in the recurrence of
arrhythmia between the two groups, when only patients
treated with an ICD without anti-arrhythmic drugs are
considered (7 [39%] of 18 patients vs. 4 [80%] of 5
patients).
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